Results 91 to 100 of about 15,116 (246)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease

open access: yes, 2018
Vibhash D Sharma, Kelly E Lyons, Rajesh Pahwa Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA Abstract: Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on ...
Pahwa R, Lyons KE, Sharma VD
core  

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease

open access: yes, 2018
Robert A Hauser,1 Aaron Ellenbogen,2 Sarita Khanna,3 Suneel Gupta,3 Nishit B Modi3 1Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL, USA; 2Quest Research Institute, Bingham Farms, MI, USA; 3Impax ...
Hauser RA   +4 more
core  

Unilateral Freezing of Gait in Normal Pressure Hydrocephalus after Stroke

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Jose Portales   +2 more
wiley   +1 more source

Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease

open access: yes, 2013
Xinxin Yang, Na Wu, Lu Song, Zhenguo Liu Department of Neurology, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China Background: Levodopa remains the most effective drug for the ...
Yang X, Song L, Liu Z, Wu N
core  

Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan   +10 more
wiley   +1 more source

Clinical Progression in Alpha‐Synuclein Positive LRRK2‐PD and Sporadic Parkinson's Disease: A Longitudinal Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse   +224 more
wiley   +1 more source

New levodopa therapeutic strategies

open access: yes, 2016
During its almost half-century of use for treating Parkinson\u27s disease, levodopa therapy has permitted most patients to reverse much of this disorder\u27s symptomatology.
LeWitt, Peter A
core   +1 more source

Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease

open access: yesFrontiers in Neurology, 2019
Parkinson's disease is the second-most common neurodegenerative disorder worldwide. Besides deciphering the mechanisms that underlie the etiology of the disease, it is important to elucidate the factors that influence the efficacy of the treatment ...
Sebastiaan P. van Kessel, Sahar El Aidy
doaj   +1 more source

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date

open access: yes, 2018
Ami B Patel, Joohi Jimenez-Shahed Department of Neurology, Baylor College of Medicine, Houston, TX, USA Abstract: Inhaled levodopa is a newly emerging therapeutic option in the treatment of “off” symptoms associated with Parkinson ...
Patel AB, Jimenez-Shahed J
core  

Pseudo‐Dystonic Gait in a Preschool Child: Foot Posturing Contralateral to a Cuboid Fracture

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Allison J. Chirigos   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy